NuvOx Therapeutics, Inc.

expected

Not yet set

status

Filed with SEC

proposed ticker

NUOX

Industry

Pharmaceutical Preparations

Headquarters

United States

Incorporated in

Underwriters (from filing)

ThinkEquity LLC

Overview

— AI-generated from the filing, see note below

Business overview

NuvOx Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oxygen therapeutic solutions for diseases where hypoxia (lack of oxygen) is a major factor. The primary product candidate, NanO2, is administered intravenously and designed to enhance oxygen delivery in patients experiencing conditions such as acute ischemic stroke, GBM (glioblastoma multiforme), ARDS (acute respiratory distress syndrome), and sickle cell anemia. NanO2 has undergone several clinical trials, showing potential to maintain oxygenation in affected tissues and improve treatment efficacy for various critical health conditions.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Innovative oxygen therapeutic solutions
Focus on critical unmet medical needs
Use of FDA-approved clinical trial pathways
Established clinical trial data showing safety and efficacy
Orphan drug designation for specific treatment areas

Risk factors

Limited operating history and capital resources
Dependency on successful regulatory approval and market acceptance of NanO2
Competition from better-funded and experienced companies
Uncertainty in generating revenues and profitability
Challenges in conducting clinical trials and establishing commercial operations

Use of proceeds

The net proceeds from this offering are intended to be used to complete current clinical trials, including those for GBM and ARDS, and prepare for a pivotal Phase III trial for GBM.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The proposed ticker is NUOX. Underwriters on the deal include ThinkEquity LLC. NuvOx Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with NuvOx Therapeutics, Inc..

Biotech IPOs United States IPOs ThinkEquity LLC IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/nuvox-therapeutics" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="NuvOx Therapeutics, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/nuvox-therapeutics?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/nuvox-therapeutics/opengraph-image

Attribution text

NuvOx Therapeutics, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/nuvox-therapeutics?utm_source=embed&utm_medium=text&utm_campaign=nuvox-therapeutics

Track this IPO

Get emailed when NuvOx Therapeutics, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

What is NuvOx Therapeutics, Inc.'s ticker symbol?

NuvOx Therapeutics, Inc.'s proposed ticker is NUOX.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Sep 16, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.